China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at the starting dose specified in the clinical protocol in the first patient with systemic lupus erythematosus (SLE) in an investigator-initiated trial (IIT).
Therapy Details
KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, was developed via CARsgen’s THANK-u Plus platform. The therapy is currently subject to an IIT for B-cell tumors and an IIT for SLE and systemic sclerosis. This marks a significant step in the clinical development of KJ-C2219 for the treatment of autoimmune diseases.-Fineline Info & Tech
Leave a Reply